KBC Group NV grew its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 6.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,496 shares of the medical equipment provider’s stock after purchasing an additional 1,329 shares during the period. KBC Group NV’s holdings in Zimmer Biomet were worth $2,517,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. CWA Asset Management Group LLC boosted its position in shares of Zimmer Biomet by 1.8% during the 2nd quarter. CWA Asset Management Group LLC now owns 1,952 shares of the medical equipment provider’s stock valued at $251,000 after acquiring an additional 34 shares in the last quarter. Advisory Services Network LLC boosted its position in shares of Zimmer Biomet by 1.0% during the 2nd quarter. Advisory Services Network LLC now owns 3,690 shares of the medical equipment provider’s stock valued at $474,000 after acquiring an additional 37 shares in the last quarter. Armor Investment Advisors LLC boosted its position in shares of Zimmer Biomet by 2.0% during the 2nd quarter. Armor Investment Advisors LLC now owns 2,600 shares of the medical equipment provider’s stock valued at $334,000 after acquiring an additional 50 shares in the last quarter. Geneva Advisors LLC boosted its position in shares of Zimmer Biomet by 2.7% during the 2nd quarter. Geneva Advisors LLC now owns 2,107 shares of the medical equipment provider’s stock valued at $271,000 after acquiring an additional 55 shares in the last quarter. Finally, Sandy Spring Bank boosted its position in shares of Zimmer Biomet by 5.4% during the 2nd quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock valued at $166,000 after acquiring an additional 66 shares in the last quarter. Institutional investors and hedge funds own 86.24% of the company’s stock.

Several brokerages have recently weighed in on ZBH. Oppenheimer set a $137.00 target price on shares of Zimmer Biomet and gave the company a “buy” rating in a research report on Monday, August 14th. Gabelli began coverage on shares of Zimmer Biomet in a research report on Thursday, August 24th. They set a “buy” rating and a $142.00 target price on the stock. Morgan Stanley decreased their target price on shares of Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating on the stock in a research report on Thursday, November 2nd. SunTrust Banks reiterated a “buy” rating and set a $136.00 target price on shares of Zimmer Biomet in a research report on Monday, October 2nd. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $120.00 target price on shares of Zimmer Biomet in a research report on Friday, November 3rd. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $133.71.

Zimmer Biomet Holdings Inc (NYSE ZBH) traded down $1.40 during trading hours on Friday, reaching $113.38. 1,656,416 shares of the company’s stock were exchanged, compared to its average volume of 1,141,137. The firm has a market capitalization of $22,956.39, a price-to-earnings ratio of 14.05, a PEG ratio of 1.76 and a beta of 1.15. Zimmer Biomet Holdings Inc has a 52-week low of $100.81 and a 52-week high of $133.49. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The company had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.83 billion. During the same period in the prior year, the firm posted $1.79 earnings per share. The company’s revenue was down .8% on a year-over-year basis. analysts expect that Zimmer Biomet Holdings Inc will post 8.03 earnings per share for the current fiscal year.

WARNING: This news story was published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/zimmer-biomet-holdings-inc-zbh-shares-bought-by-kbc-group-nv/1755983.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.